These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38670860)

  • 21. Should small papillary thyroid cancer be observed? A population-based study.
    Nilubol N; Kebebew E
    Cancer; 2015 Apr; 121(7):1017-24. PubMed ID: 25425528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma.
    Carhill AA; Litofsky DR; Sherman SI
    Endocr Pract; 2015 May; 21(5):461-7. PubMed ID: 25536972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011.
    Malmgren JA; Calip GS; Atwood MK; Mayer M; Kaplan HG
    Cancer; 2020 Jan; 126(2):390-399. PubMed ID: 31639221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype.
    Zanardi E; Di Meglio A; Boccardo C; Zinoli L; Salvi S; Rubagotti A
    Oncol Res Treat; 2020; 43(7-8):362-371. PubMed ID: 32512573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.
    Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M
    Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas.
    Paul Wright G; Davis AT; Koehler TJ; Melnik MK; Chung MH
    Ann Surg Oncol; 2014 Oct; 21(11):3497-503. PubMed ID: 24838367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of a Nomogram for Prognosis Prediction in Patients with Synchronous Primary Thyroid and Breast Cancer Based on SEER Database.
    Huo M; Zhang J; Hou M; Li J; Bai N; Xu R; Guo J
    Cancer Invest; 2024 Mar; 42(3):212-225. PubMed ID: 38527848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
    Shao HY; Hao BT; Gao FX
    Breast J; 2023; 2023():7028189. PubMed ID: 38021219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.
    Romano AM; Wages NA; Smolkin M; Fortune KL; Atkins K; Dillon PM
    Breast Dis; 2015; 35(2):103-11. PubMed ID: 25567000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico.
    Ortiz AP; Frías O; Pérez J; Cabanillas F; Martínez L; Sánchez C; Capó-Ramos DE; González-Keelan C; Mora E; Suárez E
    Cancer Med; 2013 Jun; 2(3):343-50. PubMed ID: 23930211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race.
    Zhou J; Cueto J; Ko NY; Hoskins KF; Nabulsi NA; Asfaw AA; Hubbard CC; Mitra D; Calip GS; Law EH
    Breast; 2021 Oct; 59():367-375. PubMed ID: 34419726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study.
    Lammers SWM; Meegdes M; Vriens IJH; Voogd AC; de Munck L; van Nijnatten TJA; Keymeulen KBMI; Tjan-Heijnen VCG; Geurts SME
    ESMO Open; 2024 May; 9(5):103008. PubMed ID: 38677006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR; Jiang YZ; Yu KD; Shao ZM
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid Cancer Benefits the Prognosis of Ovarian Cancer: A SEER-Based Study.
    Yang Q; Wu Z; He X; Yu L; Zhang X; Lei K
    Adv Ther; 2019 May; 36(5):1211-1220. PubMed ID: 30879254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
    Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
    Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors of patients with thyroid cancer and bone metastasis at presentation.
    Yao Z; Yao Y; Zhou X; Shen S; Hu X; Gao Q
    Front Endocrinol (Lausanne); 2024; 15():1344795. PubMed ID: 38899008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.